medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-11-202-207medsovet-1943Research ArticleДИССЕРТАНТDISSERTANTИСТОРИЯ РОЖДЕНИЯ СТАТИНОВ НОВЫЕ ПЕРСПЕКТИВЫHISTORY OF STATINS DEVELOPMENT. NEW PROSPECTSДрееваЗ. В.DreevaZ. V.

Москва

Postgraduate.

Moscow

АгеевФ. Т.AgeevF. T.

Доктор медицинских наук, профессор.

Москва

MD, Prof.

Moscow

Научно-исследовательский институт клинической кардиологии им. А.Л. Мясникова Российского кардиологического научнопроизводственного комплекса Минздрава РоссииРоссияMyasnikov Scientific and Research Institute of Clinical Cardiology of the Russian Cardiologic Scientific and Production Complex of the Ministry of Health of RussiaRussian Federation201704072017011202207Copyright © Дреева З.В., Агеев Ф.Т., 20172017Дреева З.В., Агеев Ф.Т.Dreeva Z.V., Ageev F.T.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1943

Статины  используются  со второй  половины XX века. Прошло   достаточно времени, чтобы понять истинное значение роли статинов в лечении сердечно-сосудистых заболеваний. Большой вклад в этом напправлении вносит новая область в изучении статинов – сердечная  недостаточность с сохранной фракцией выброса.

Statins have been used since the second half of the XXth century. It’s been a while time to understand the importance of statins in the treatment of cardiovascular disorders.Statins therapy in HFPEF is a new area that contributes significantly to the treatment of heart disease.

статиныингибиторы ГМГ-КоА-редуктазыдиастолическая функция левого желудочкасердечная недостаточность с сохранной фракцией выбросаstatinsinhibitors of HMG-COA reductase diastolic function of the left ventricleheart failure with preserved ejection fractionReferencesSteinberg D. Chemotherapeutic approaches to the problem of hyperlipidemia. Adv Pharmacol, 1962, 1: 59-159.Steinberg D. Chemotherapeutic approaches to the problem of hyperlipidemia. Adv Pharmacol, 1962, 1: 59-159.Cottet J, Redel J, Krumm-Heller C, and Tricaud ME. Hypocholesterolemic property of sodium phenylethylacetate (22 TH) in the rat. Bull Acad Natl Med, 1953, 137: 441-442.Cottet J, Redel J, Krumm-Heller C, and Tricaud ME. Hypocholesterolemic property of sodium phenylethylacetate (22 TH) in the rat. Bull Acad Natl Med, 1953, 137: 441-442.Cottet J, Mathivat A, and Redel J. Therapeutic study of a synthetic hypocholesterolemic agent: phenyl-ethyl-acetic acid. Presse Med, 1954, 62: 939-941.Cottet J, Mathivat A, and Redel J. Therapeutic study of a synthetic hypocholesterolemic agent: phenyl-ethyl-acetic acid. Presse Med, 1954, 62: 939-941.Fredrickson DS and Steinberg D. Inhibitors of cholesterol biosynthesis and the problem of hypercholesterolemia. Ann N Y Acad Sci, 1956, 64: 579-589.Fredrickson DS and Steinberg D. Inhibitors of cholesterol biosynthesis and the problem of hypercholesterolemia. Ann N Y Acad Sci, 1956, 64: 579-589.Steinberg D, Fredrickson DS and Avigan J. Effects of 4-cholestenone in animals and in man. Proc Soc Exp Biol Med, 1958, 97: 784-790.Steinberg D, Fredrickson DS and Avigan J. Effects of 4-cholestenone in animals and in man. Proc Soc Exp Biol Med, 1958, 97: 784-790.Steinberg D and Fredrickson DS. Inhibition of lipid synthesis by alpha-phenyl-N-butyrate and related compounds. Proc Soc Exp Biol Med, 1955, 90: 232-236.Steinberg D and Fredrickson DS. Inhibition of lipid synthesis by alpha-phenyl-N-butyrate and related compounds. Proc Soc Exp Biol Med, 1955, 90: 232-236.Fredrickson DS and Steinberg D. Failure of alpha-phenylbutyrate and beta-phenylvalerate in treatment of hypercholesterolemia. Circulation, 1957, 15: 391-396.Fredrickson DS and Steinberg D. Failure of alpha-phenylbutyrate and beta-phenylvalerate in treatment of hypercholesterolemia. Circulation, 1957, 15: 391-396.Oliver MF and Boyd GS. Effect of phenylethylacetic acid and its amide (hyposterol) on the circulating lipids and lipoproteins in man. Lancet, 1957, 273: 829-830.Oliver MF and Boyd GS. Effect of phenylethylacetic acid and its amide (hyposterol) on the circulating lipids and lipoproteins in man. Lancet, 1957, 273: 829-830.Grande F, Anderson JT and Keys A. Phenyl butyramide and the serum cholesterol concentration in man. Metabolism, 1957, 6: 154-160.Grande F, Anderson JT and Keys A. Phenyl butyramide and the serum cholesterol concentration in man. Metabolism, 1957, 6: 154-160.Fredrickson DS, Peterson RE and Steinberg D. Inhibition of adrenocortical steroid secretion by delta 4-cholestenone. Science, 1958, 127: 704-705.Fredrickson DS, Peterson RE and Steinberg D. Inhibition of adrenocortical steroid secretion by delta 4-cholestenone. Science, 1958, 127: 704-705.Tomkins GM, Nichols CW, Chapman DD et al. Use of delta 4-cholestenone to reduce the level of serum cholesterol in man. Science, 1957, 125: 936-937.Tomkins GM, Nichols CW, Chapman DD et al. Use of delta 4-cholestenone to reduce the level of serum cholesterol in man. Science, 1957, 125: 936-937.Blohm TR and MacKenzie RD. Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). Arch Biochem Biophys, 1959, 85: 245-249.Blohm TR and MacKenzie RD. Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). Arch Biochem Biophys, 1959, 85: 245-249.Avigan J, Steinberg D, Thompson MJ and Mosettig E. Mechanism of action of MER-29, an inhibitor of cholesterol biosynthesis. Biochem Biophys Res Commun, 1960, 2: 63-65.Avigan J, Steinberg D, Thompson MJ and Mosettig E. Mechanism of action of MER-29, an inhibitor of cholesterol biosynthesis. Biochem Biophys Res Commun, 1960, 2: 63-65.Yamamoto A, Sudo H, and Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis, 1980, 35: 259-266.Yamamoto A, Sudo H, and Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis, 1980, 35: 259-266.Mabuchi H, Haba T, Tatami R et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med, 1981, 305: 478-482.Mabuchi H, Haba T, Tatami R et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med, 1981, 305: 478-482.Сергиенко И.В. История появления статинов. Атеросклероз и дислипидемии, 2011, 1. http://cyberleninka.ru/article/n/istoriya-poyavleniyastatinov.Сергиенко И.В. История появления статинов. Атеросклероз и дислипидемии, 2011, 1. http://cyberleninka.ru/article/n/istoriya-poyavleniyastatinov.

The authors declare that there are no conflicts of interest present.